Clinical Trials

Ongoing Phase 3 trial of Celiprolol in Vascular Ehlers Danlos Syndrome

NOW ENROLLING COL3A1 positive VEDS patients (15 years and older)

The DiSCOVER trial is being conducted by Zevra to evaluate the efficacy and safety of celiprolol.

Celiprolol is a selective adrenoceptor modulator believed to decrease mechanical stress on the vascular wall of large arteries and hollow organs, such as the uterus. It is an investigational medication for the treatment of Vascular Ehlers Danlos Syndrome (VEDS).

The clinical trial intends to enroll 150 COL3A1 positive VEDS patients. 50 patients will receive placebo and 100 patients will receive celiprolol up to 400 mg/day (200mg bid). The trial will conclude when 46 qualifying events (fatal or non-fatal cardiac event such as rupture of dissection, uterine rupture, colon rupture and/or unexplained sudden death) have been reported.